Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1⁺) advanced ovarian cancer: Updated analysis of KEYNOTE-028.

5513 Background: Overexpression of the PD-1 ligand PD-L1 has been demonstrated in ovarian cancer and may hinder an effective antitumor immune response. A preliminary analysis of the ovarian cancer cohort of the KEYNOTE-028 study (NCT02054806) suggested that the PD-1 inhibitor pembrolizumab has promising antitumor activity in pts with PD-L1 + advanced ovarian cancer. An updated analysis of the ovarian cancer cohort based on 15.5 months of...